Glycobiology: Global Markets for Diagnostics and Therapeutics
- September 2016 •
- 137 pages •
- Report ID: 4186198
- Evaluate new commercial opportunities in the glycobiology diagnostics, therapeutics and research tools market.
- Analyze major market participants, including current and future market trends of the glycobiology industry.
- Analyze the drivers and challenges in each segment of the glycobiology market.
- Gain information about significant players in the field of glycobiology industry.
- The global market for glycobiology will grow from nearly $24.6 billion in 2016 to nearly $50.1 billion by 2021 with a compound annual growth rate (CAGR) of 15.3% for the period of 2016-2021.
- The therapeutics market is the largest segment of the glycobiology industry and will grow from $19.0 billion in 2016 to $40.0 billion by 2021, with a CAGR of 16.1%.
- The diagnostics market is expected to increase from $5.5 billion in 2016 to $10.0 billion by 2021, with a CAGR of 12.7%.
Introduction & Scope
STUDY GOALS AND OBJECTIVES
This BCC Research report, Glycobiology: Global Markets for Diagnostics and Therapeutics, provides an overview of glycans as novel drugs as therapeutic targets,
glycan-based diagnostics and a detailed analysis of the competitive environment, including potential new markets for novel products, biomarkers and drug development. The study includes information about significant players in this field of study, trends and challenges and other information affecting the development of the market for glycobiology.
REASONS FOR DOING THIS STUDY
The importance of carbohydrates in biological processes has long been underappreciated. Nevertheless, with new tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates, the understanding of these biomolecules is rapidly improving. This knowledge is also yielding promising candidates for carbohydrate-based diagnostics, drugs and vaccines. Importantly, the study of such molecules is technically challenging as no sequencing tool, such as that used in proteomics or genomics, is available. However, following on from genomics and proteomics, there is increasing recognition of the importance of carbohydrate-based molecules in basic cellular processes. The central role of saccharides in cellular interactions means that novel oligosaccharides are of value in R&D programs addressing a wide range of therapeutic areas, including inflammation, immunity, oncology, neurodegenerative disease, infection and more.
Because of their essential function in many cellular processes, carbohydrates are also important biomarkers in diagnostic assay development. This report will highlight the main segments of the glycobiology industry and its major market participants, including current and future market trends. Drivers and challenges in each segment of this industry will be discussed in detail, with a forecast from 2016 through 2021.
SCOPE AND FORMAT
This report presents current and important business tools to evaluate new commercial opportunities in glycobiology diagnostics, therapeutics and research tools market. The geographic scope of this study covers companies in the U.S. and worldwide. This market is complex and consists of number of different segments, each affected differently by scientific and technological development. The report identifies the main positive and negative factors in each segment and forecasts further trends, products and assay developments.
METHODOLOGY AND INFORMATION SOURCES
The research methodology was mainly qualitative in nature and used a triangulation approach to increase the credibility and validity of the data. Initially, a comprehensive and exhaustive search of the literature on diagnostics, therapeutics and already marketed research tools products was conducted. These secondary sources included drug development, science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis was also conducted. In a second phase, a series of semi-structure interviews were conducted with company representatives, bench scientist, marketing representative and other personnel at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies. These were a rich source of data. Subsequent analysis of the documents and interviews notes was iterative.
This report is intended for business development professionals, entrepreneurs and other investment groups in order fully understand and evaluate properly each segment of the glycobiology market. It provides a company’s corporate development new insight into their competitor’s position and shows new opportunities otherwise overlooked or less known to the public.